EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieÄquivalenzstudieOpen Access · CC BY 4.0

Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE): A Multicenter Randomized Clinical Trial

Cristina Mosconi, Makoto Taninokuchi Tomassoni, Sara Zanella, Alexandro Paccapelo, Giovanni Marasco, Simone Gusmini, Francesca Ratti, Diego Palumbo, Sandro Sironi, Riccardo Muglia, Marco Mario Edgardo Fronda, Marco Calandri und 6 weitere

CardioVascular and Interventional Radiology · 2026

DOI: 10.1007/s00270-026-04487-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CardioVascular and Interventional Radiology, 2026. Verfasst von Cristina Mosconi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni 15, Bologna, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Embolization, Therapeutic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare transarterial embolization (TAE) and drug-eluting microspheres transarterial chemoembolization (DEM-TACE) in the treatment of hepatocellular carcinoma (HCC) through a non-inferiority randomized clinical trial. Materials and Methods Patients diagnosed with unresectable HCC were randomly assigned to either the TAE or DEM-TACE group. The primary endpoint was time to progression (TTP), and secondary endpoints included overall survival, hospitalization stay, tumor response rates, and severe adverse events (SAE).

Results

At the end of the trial, a total of 111 patients (56 TAE and 55 DEM-TACE) were enrolled between 2019 and 2022. The median TTP was similar between TAE and DEM-TACE (7.56 vs. 7.98 months, p = 0.432). In patients with confirmed disease progression, the mean TTP was 6.68 vs. 8.43 months for TAE and DEM-TACE, respectively, with a mean difference of 1.75 months (95% CI − 1.47–4.97), falling within the predefined equivalence range; two one side test (TOST) analysis confirmed equivalence ( p < 0.001 and p = 0.022 for lower and upper bounds. Overall survival, tumor response rates, and adverse events were also not statistically different between groups ( p > 0.05 for each outcome). Finally, Days of hospitalization were not statistically different (median 4 days for both arms, p = 0.638).

Conclusion

TAE and DEM-TACE had comparable results in the treatment of early and intermediate stage unresectable HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticEmbolization, TherapeuticHumansFemaleMaleMicrospheresMiddle AgedAgedTreatment Outcome

Stichwörter der Autor:innen

ChemoembolizationDrug-eluting microspheres embolizationHepatocellular carcinomaRandomized clinical trialTransarterial embolization

Autor:innen und Institutionen

  • Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni 15, Bologna, Italy.
  • Department of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni 15, Bologna, Italy. makoto.taninokuchitomassoni@aosp.bo.it.
  • Epidemiology and Statistics, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Department of Radiology, IRCCS San Raffaele Hospital, Milan, Italy.
  • Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milano Vita Salute San Raffaele University, Milan, Italy.

Förderung

  • Agenzia Italiana del Farmaco, Ministero della Salute

Zitieren

APA

Mosconi, C., Taninokuchi Tomassoni, M., Zanella, S., Paccapelo, A., Marasco, G., Gusmini, S., Ratti, F., Palumbo, D., Sironi, S., Muglia, R., Fronda, M. M. E., Calandri, M., Fonio, P., Marra, P., Doriguzzi Breatta, A., Cucchetti, A., De Cobelli, F., & Renzulli, M. (2026). Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE): A Multicenter Randomized Clinical Trial. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-026-04487-3

Vancouver

Mosconi C, Taninokuchi Tomassoni M, Zanella S, Paccapelo A, Marasco G, Gusmini S, et al. Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE): A Multicenter Randomized Clinical Trial. CardioVascular and Interventional Radiology. 2026. doi:10.1007/s00270-026-04487-3

BibTeX
@article{Mosconi2026,
  author = {Mosconi, Cristina and Taninokuchi Tomassoni, Makoto and Zanella, Sara and Paccapelo, Alexandro and Marasco, Giovanni and Gusmini, Simone and Ratti, Francesca and Palumbo, Diego and Sironi, Sandro and Muglia, Riccardo and Fronda, Marco Mario Edgardo and Calandri, Marco and Fonio, Paolo and Marra, Paolo and Doriguzzi Breatta, Andrea and Cucchetti, Alessandro and De Cobelli, Francesco and Renzulli, Matteo},
  title = {Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE): A Multicenter Randomized Clinical Trial},
  journal = {CardioVascular and Interventional Radiology},
  year = {2026},
  doi = {10.1007/s00270-026-04487-3}
}
Kostenlos starten →